跳至主要内容
临床试验/NCT07831057
NCT07831057招募中不适用

Temperature Optimization in Afebrile Septic PatienTs

Matt Harmon1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2026年7月17日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
50
试验地点
1
主要终点
Proteomics

研究概览

简要总结

The goal of this interventional study is to learn if external warming works to treat patients with a serious systemic infection (i.e. sepsis) that do not have fever. These patients have a higher risk of dying than patients with fever. It is possible that these patients might benefit from artificial external warming with the means to increase body temperature. It is unknown what the mechanism is, but it might be related to the immune system and how the body manages blood pressure and perfusion.

The main questions to answer are:

  • Does external warming of the body influence certain inflammatory proteins in the blood?
  • Does external warming of the body influence prognosis and/or clinical condition? Researchers will compare external warming to standard clinical practice to see if external warming works to treat sepsis without fever.

Participants will:

- receive treatment with external warming or treatment according to clinical practice

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Sepsis according to the SEPSIS-3 definition
  • Sedated and intubated
  • Highest temperature < 38,3 degrees Celsius

排除标准

  • A potential participant who meets any of the following criteria will be excluded from participation in this study:
  • Patients with immunologic diseases:
  • human immunodeficiency virus
  • neutropenia
  • history of chronic infection with hepatitis B or C virus
  • Patients using immune suppressing medications:
  • treatment with corticosteroids at a dose of > 300 mg/day hydrocortisone or equivalent at the time of enrollment;
  • Tacrolimus
  • Mycophenolate mofetil
  • Ciclofosfamide
  • Patients with a contraindication for therapeutic hyperthermia:
  • cardiac arrest
  • acute ischemic stroke
  • acute coronary syndrome
  • traumatic brain injury
  • spinal cord injury
  • sickle cell disease
  • multiple sclerosis
  • Pregnancy
  • Moribund patients (expected death within 48 hours)
  • Contraindications to forced air warming devices per manufacture instructions (i.e. ischemic limbs)

研究组 & 干预措施

External Warming

Experimental

Intervention with External Warming

干预措施: External Warming (Other)

Control

No Intervention

Control group according to standard clinical practice

结局指标

主要结局

Proteomics

时间窗: From enrollment until 48 hours after enrollment

Delta proteomics pathway analysis between baseline and after 48 hours of enrollment.

次要结局

  • Mortality(30 days)
  • Organ failure(until end of ICU stay, approximately 30 days)
  • Length of ICU stay(until end of ICU stay, approximately 30 days)
  • Nosocomial infections(until end of ICU stay, approximately 30 days)
  • Length of hospital stay(until discharge, approximately 30 days until 3 months)
  • Microcirculation(From enrollment until 48 hours after enrollment)
  • Hemodynamics(From enrollment until 48 hours after enrollment)
  • Mitochondrial oxygen tension(From enrollment until 48 hours after enrollment)

研究者

发起方
Matt Harmon
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Matt Harmon

Principal Investigator

Erasmus Medical Center

研究点 (1)

Loading locations...

相似试验